Author of the article: Brigid Goulem
Publishing date: May 12, 2021  â¢Â 9 hours ago  â¢Â 3 minute read Dr. Joseph Pater with his Canadian Cancer Society Award for Excellence in Cancer Research: Lifetime Contribution Prize. Photo by Queen s University /Supplied Photo
Article content
There were many variables that shaped Dr. Joseph Paterâs decision to research cancer treatments â his wife, who was a nurse, his father, who died of colon cancer when he was young, and his medical mentors.
âSome of the people who trained me, the residents and the faculty members, the ones who impressed me, the people I admired, they worked in this area,â Pater explained in a phone interview.
Queen’s health researcher receives inaugural Canadian Cancer Society Lifetime Contribution Prize
May 12, 2021- Joseph Pater, Professor Emeritus at Queen’s University, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS). The award recognizes an esteemed Canadian investigator whose contributions, vision, and leadership have enhanced the Canadian cancer research landscape to significantly benefit the lives of people with cancer.
“I am thrilled and humbled to be named the first recipient of the Canadian Cancer Society’s Lifetime Contribution Prize, said Dr. Joseph Pater, Professor Emeritus at Queen’s University and recipient of the Canadian Cancer Society Lifetime Achievement Prize.
There were many variables that shaped Dr. Joseph Pater’s decision to research cancer treatments his wife, who was a nurse, his father, who died of colon…
Author of the article: Brigid Goulem
Publishing date: May 12, 2021  â¢Â May 13, 2021  â¢Â 3 minute read Dr. Joseph Pater with his Canadian Cancer Society Award for Excellence in Cancer Research: Lifetime Contribution Prize. Photo by Queen s University /Supplied Photo
Article content
There were many variables that shaped Dr. Joseph Paterâs decision to research cancer treatments â his wife, who was a nurse, his father, who died of colon cancer when he was young, and his medical mentors.
âSome of the people who trained me, the residents and the faculty members, the ones who impressed me, the people I admired, they worked in this area,â Pater explained in a phone interview.
This article is a collaboration between MedPage Today and:
A year ago, ASCO released a clinical practice guideline on systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. Part two has now been released, and it focuses on patients with stage IV NSCLC with driver alterations.
The guideline is a result of potentially practice-changing evidence published since the last update [in 2017], noted Gregory Masters, MD, of the ChristianaCare Helen F. Graham Cancer Center and Research Institute in Newark, Delaware, and colleagues.
The updated guideline offers 41 recommendations, including the following:
Patients should be offered targeted therapies against